Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...
Why Trump’s threatened pharmaceutical tariffs would be unlikely to lower prices in the U.S.
U.S. President Donald Trump has repeatedly mentioned pharmaceuticals as another industry that could be targeted by tariffs, ...
10 growth stocks in the S&P 500's bargain sector
The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...
news.crunchbase2h
Funding Is Flush For Startups Focused On Treating Pain
As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
Times News18h
FDA approves painkiller designed to eliminate risk of addiction
Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.
BioSpace23h
Algiax’s Non-Opioid Drug Reduces Neuropathic Pain in Mid-Stage Trial
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
BioPharma Dive8h
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Investor's Business Daily on MSN23h
Dow Jones Giant Merck Beats Quarterly Expectations. But Will Its Light Guidance Slug Shares?
Merck topped Wall Street's fourth-quarter expectations Tuesday, but Merck stock could take a hit on lighter-than-expected 2025 sales guidance.